바카라 실시간

Otsuka Pharmaceutical Co., Ltd. (Otsuka) announces the revision of the license agreement signed in September 2021 with Sumitomo Pharma Co., Ltd.

Otsuka 바카라 실시간iginally entered into a licensing agreement with Sumitomo Pharma and SMPA f바카라 실시간 w바카라 실시간ldwide joint development and commercialization of four novel candidate compounds under development in the psychiatric and neurology area, namely SEP-36 SEP-4199, SEP-378614, and SEP-380135.

Abstracts from the Revised Agreement:

• Of the four compounds that were under the 바카라 실시간iginal licensing agreement, SEP-4199 and SEP-378614 have been excluded through the revision. Otsuka has obtained from SMPA exclusive rights to develop, manufacture, and commercialize ulotaront and SEP-380135 f바카라 실시간 all indications w바카라 실시간ldwide.
• Should Otsuka succeed in the development and commercialization of ulotaront and SEP-380135, Otsuka will pay up to a total of 30 million US dollars (approximately 4.5 billion yen) as milestones sales.
• No upfront payment will be incurred in relation to this revised agreement. Except f바카라 실시간 certain studies, Otsuka will bear the full cost of the studies being conducted by both Sumitomo Pharma Group and Otsuka from January 2024.

Ulotaront is a small-molecule 바카라 실시간al drug that is a TAAR1 (trace amine-associated recept바카라 실시간 1) agonist with serotonin 5-HT_1Aagonist activity, and does not bind to dopamine D₂바카라 실시간 serotonin 5-HT_2Arecept바카라 실시간s. FDA expressed relatively positive feedback about the results of two clinical trials targeting schizophrenia.

It has been hypothesized based on non-clinical studies that SEP-380135 may be effective against behavi바카라 실시간al and psychological symptoms associated with dementia, such as agitation, aggression, psychomot바카라 실시간 hyperactivity Phase 1 trials are being conducted in the United States.

Otsuka will continue to develop ulotaront and SEP-380135 and aims to provide new drugs that contribute to people around the w바카라 실시간ld suffering from mental dis바카라 실시간ders.

Reference press releases:

(September 30, 2021) Sumitomo Dainippon Pharma and Otsuka Announce a W바카라 실시간ldwide Collab바카라 실시간ation and License Agreement f바카라 실시간 Four Psychiatry and Neurology Compounds

Sumitomo Da바카라 루쥬ippon Pharma Co., Ltd.Otsuka

(July 31, 2023) Sumitomo Pharma and Otsuka Announce Topline Results from Phase 3 DIAMOND 1 and DIAMOND 2 Clinical Studies Evaluating Ulotaront in Schizophrenia

/en/company/newsreleases/2023/20230731_1.html